Company Filing History:
Years Active: 1999-2000
Title: Innovations by Robert J Deans in Cell Selection Technology
Introduction
Robert J Deans is an accomplished inventor based in Claremont, CA (US). He has made significant contributions to the field of cell selection technology, holding 2 patents that focus on innovative methods for the release of selected cells from heterogeneous cell suspensions.
Latest Patents
His latest patents include methods for positive and positive/negative cell selection mediated by peptide release. The first patent provides a non-enzymatic method for the release of cells that have been selected through antibody-mediated binding to solid supports. This method involves forming a complex within the cell suspension, which includes a solid support linked to a primary monoclonal antibody bound to a cell surface antigen on the target cells. The complex is then separated from the suspension and contacted with a specific peptide that binds to the primary antibody, displacing it from the cell surface antigen and releasing the target cell. The second patent outlines similar methods for positive/negative cell selection, specifically targeting CD34+ hematopoietic stem cells while purging undesired tumor cells or lymphocytes. This purified CD34+ cell composition is particularly useful for reinfusion to cancer patients after high-dose therapy to help reconstitute their immune systems.
Career Highlights
Robert J Deans is currently associated with Nexell Therapeutics Inc., where he continues to advance his research and innovations in cell selection technologies. His work has the potential to significantly impact cancer treatment and regenerative medicine.
Collaborations
He collaborates with notable colleagues such as Janet Tseng-Law and Joan A Kobori, contributing to a dynamic research environment focused on improving cell selection methods.
Conclusion
Robert J Deans is a pioneering inventor whose work in cell selection technology is paving the way for advancements in medical treatments. His innovative patents and collaborations highlight his commitment to improving patient outcomes in the field of oncology.